Impel Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system. The Company is rapidly advancing a product pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) technology with well- established therapeutics, including Trudhesa® for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. To learn more about Impel Pharmaceuticals, please visit our website at http://impelpharma.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 14, 2022
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7K: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch Impel to Host Investor Conferenc...
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
Nov 08, 2022
SEATTLE, Nov. 8, 2022 — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian A...
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Nov 07, 2022
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announ...